Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-25T12:15:16.350Z Has data issue: false hasContentIssue false
  • English
  • Français

Antibodies in Serum of Patients with Alzheimer's Disease Cause Immunolysis of Cholinergic Nerve Terminals from the Rat Cerebral Cortex

Published online by Cambridge University Press:  18 September 2015

H.F. Bradford ,
P. Foley ,
M. Docherty ,
H. Fillit ,
V.N. Luine ,
B. McEwen ,
G. Bucht ,
B. Winbald  and
J. Hardy
H.F. Bradford*
Affiliation:
Department of Biochemistry, Imperial College of Science and Technology, London, Rockefeller University, New York
P. Foley
Affiliation:
Department of Biochemistry, Imperial College of Science and Technology, London, Rockefeller University, New York
M. Docherty
Affiliation:
Department of Biochemistry, Imperial College of Science and Technology, London, Rockefeller University, New York
H. Fillit
Affiliation:
Department of Biochemistry, St. Mary's Hospital Medical School, London, Rockefeller University, New York
V.N. Luine
Affiliation:
Department of Biochemistry, St. Mary's Hospital Medical School, London, Rockefeller University, New York
B. McEwen
Affiliation:
Department of Biochemistry, St. Mary's Hospital Medical School, London, Rockefeller University, New York
G. Bucht
Affiliation:
Department of Geriatric Medicine, University of Umea, Sweden
B. Winbald
Affiliation:
Department of Geriatric Medicine, Karolinska Institute, Sweden
J. Hardy
Affiliation:
Department of Biochemistry, St. Mary's Hospital Medical School, London, Rockefeller University, New York
*
Department of Biochemistry, Imperial College of Science and Technology, London SW7 2AZ UK
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A blind study showing that serum from patients with Alzheimer's disease causes immunolysis of mammalian brain synaptosomes is reported. Control, aged-matched, sera were largely without effect. The immunolysis was directed mainly against cholinergic synaptosomes. The data support the hypothesis that autoimmune mechanisms may operate in the pathogenesis of Alzheimer's disease.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 16 , Issue S4 , November 1989 , pp. 528 - 534
Copyright
Copyright © Canadian Neurological Sciences Federation 1989

References

REFERENCES

1.Hardy, J, Adolfsson, R, Alafuzoff, I, et al. Transmitter deficits in Alzheimer’s disease. Neurochem lnt 1985; 2: 545–63.CrossRefGoogle Scholar
2.Hardy, J, Mann, DMA, Wester, P, et al. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer’s disease. Neurobiol Aging 1986; 7: 489–502.CrossRefGoogle ScholarPubMed
3.Sims, NR, Bowen, DM, Allen, SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983; 40: 503–509.CrossRefGoogle ScholarPubMed
4.Rossor, MN, Emson, PC, Mountjoy, CQ, et al. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of the Alzheimer type. Neurosci Lett 1980; 20: 373–377.CrossRefGoogle Scholar
5.Hardy, J, Cowburn, R, Barton, A, et al. Region-specific loss of glutamate innervation in Alzheimer’s disease. Neurosci Lett 1987; 73: 77–80.CrossRefGoogle ScholarPubMed
6.Greenamyre, TJ, Penny, JB, Young, AB, et al. Alteration in L-glutamate binding in Alzheimer’s and Huntingdon’s diseases. Science 1985; 227: 1496–1499.CrossRefGoogle Scholar
7.Akiyama, H, McGeer, PL, Itagaki, S, et al. Loss of glutaminase-positive cortical neurons in Alzheimer’s disease. Neurochem Res 1989; 14: 353–358.CrossRefGoogle ScholarPubMed
8.Rosser, MN, Svendsen, C, Hunt, SP, et al. The substantia innominata in Alzheimer’s disease: An histochemical and biochemical study of cholinergic marker enzymes. Neurosci Lett 1982; 28: 217–222.CrossRefGoogle Scholar
9.Wilcock, GK, Esiri, MM, Bowen, DM, et al. Alzheimer’s disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982; 57: 407–417.CrossRefGoogle ScholarPubMed
10.Wurtman, RJ, Blusztajn, JK, Maire, J-C, et al. “Autocannibalisni” of choline-containing membrane phospholipids in the pathogenesis of Alzheimer’s disease - a hypothesis. Neurochem lnt 1985; 7: 369–372.CrossRefGoogle ScholarPubMed
11.Ishii, T, Haga, S. Immunoelectron microscopic localisation of immunoglobulins in amyloid fibrils of senile plaques. Acta Neuropathol 1976; 36: 243–249.CrossRefGoogle ScholarPubMed
12.Alafuzoff, I, Adolfsson, R, Bucht, G, et al. Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia. J Neurol Sci 1983; 60: 465–472.CrossRefGoogle ScholarPubMed
13.Chapman, J, Korczyn, AD, Hareuveni, M, et al. Antibodies to cholinergic cell bodies in Alzheimer–s disease. In: Fisher, A, Hanin, I, Lachman, C, eds. Alzheimer’s and Parkinson’s Diseases: Strategies for Research and Development. New York NY: Plenum Press, 1986: 329–336.CrossRefGoogle Scholar
14.Fillit, H, Luine, VN, Reisberg, B, et al. Studies of the specificity of antibrain antibodies in Alzheimer’s disease. In: Hutton, JT, Kenny, AD, eds. Senile Dementia of the Alzheimer Type. New York NY: Alan R Liss Ine 1985: 307–318.Google Scholar
15.Fillit, HM, Kemeny, E, Luine, V, et al. Antivascular antibodies in the sera of patients with senile dementia of the Alzheimer’s type. J Gerontol 1987; 42: 180–184.CrossRefGoogle ScholarPubMed
16.McRae-Degueurce, A, Booj, S, Haglid, K, et al. Antibodies in cerebrospinal fluid of some Alzheimer disease patients recognise cholinergic neurons in the rat central nervous system. Proc Natl Acad Sci USA 1987; 84: 9214–9218.CrossRefGoogle ScholarPubMed
17.Chang, CH, Teng, EL, Henderson, VW, et al. Clinical subtypes of dementia of the Alzheimer type. Neurology 1985; 35: 1544–1550.Google Scholar
18.Chapman, J, Orit, B, Korczyn, AD, et al.Antibodies to cholinergic neurons in Alzheimer’s disease. J Neurochem 1988; 51: 479–485.CrossRefGoogle ScholarPubMed
19.Foley, P, Bradford, HF, Docherty, M, et al. Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer’s disease. J Neurol 1988; 235: 466–471.CrossRefGoogle ScholarPubMed
20.Foley, P, Bradford, HF, Docherty, M, et al. Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer’s disease. Biochem Soc Trans 1987; 15: 1034–1036.CrossRefGoogle Scholar
21.Docherty, M, Bradford, HF, Wu, J-Y, et al. Evidence for specific immunolysis of nerve terminals using antisera against choline acetyltransferase, glutamate decarboxylase and tyrosine hydroxylase. Brain Res 1985; 339: 105–113.CrossRefGoogle ScholarPubMed
22.McKhann, G, Drachman, D, Folstein, M, et al. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.CrossRefGoogle ScholarPubMed
23.Reisberg, B, Ferris, SH, De Leon, MJ, et al. The Global Deterioration Scale for the assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136–1139.Google ScholarPubMed
24.Folstein, MF, Folstein, SE, McHugh, PR, et al. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12: 189–198.CrossRefGoogle Scholar
25.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington 3rd ed 1980: 205–224.Google Scholar
26.Bradford, HF, Bennett, GW, Thomas, AJ, et al. Depolarizing stimuli and the release of physiologically active amino acids from suspensions of mammalian synaptosomes. J Neurochem 1973; 21: 495–505.CrossRefGoogle ScholarPubMed
27.Fonnum, F. Radio chemical microassays for the determination of choline acetyltransferase activities. Biochem J 1969; 115: 465–472.Google Scholar
28.Vassault, A. Lactate dehydrogense, the UV method. In: Bergmeyer, HU, Bergmeyer, J, Grabi, M, eds. Methods of Enzymatic Analysis vol 3 Enzymes 1: Oxido Reductases, Transferases. Weinheim FRG: Verlay Cheme 1983: 118–136.Google Scholar
29.Joh, TH, Ross, RA, Reis, DJ, et al. A simple and sensitive assay for dopamine-ß-hydroxylase. Anal Biochem 1974; 62: 248–254.Google Scholar
30.Dixon, WJ, ed. Biomedical Data Processing Program (BMDP), Revised printing. Berkley California: University of California Press: 1983.Google Scholar
31.Docherty, M, Bradford, HF, Anderton, HB, et al. Lysis of cholinergic synaptosomes by an antiserum to choline acetyltransferase. Biochem Soc Trans 1982; 10: 368–369.CrossRefGoogle Scholar
32.Docherty, M, Bradford, HF. A cell surface antigen of cholinergic nerve terminals recognized by antisera to choline acetyltransferase. Neurosci Lett 1986; 70: 234–238.CrossRefGoogle ScholarPubMed
33.Docherty, M, Bradford, HF. Choline acetyltransferase in mammalian synaptosomes: evidence for an integral membrane-bound form. Neurochem lnt 1988; 13: 119–127.CrossRefGoogle ScholarPubMed
34.Eder-Colli, L, Amato, S, Froment, Y, et al. Amphiphilic and hydrophobic forms of choline-O-acetyltransferase in cholinergic nerve–endings of the Torpedo. Neuroscience 1986; 19: 275–287.CrossRefGoogle Scholar
35.Badamachian, M, Morris, KJ, Caroli, PT, et al. Immunological, isolectric, hydrophobic and molecular weight differences between soluble and ionically membrane-bound fractions of choline-O-acetyltransferase prepared from mouse and rat brain. Neurochem lnt 1986; 9: 409–421.CrossRefGoogle Scholar
36.Peng, JH, McGeer, PL, McGeer, EG. Membrane-bound choline acetyltransferase from human brain: purification and properties. Neurochem Res 1986; 11: 959–971.CrossRefGoogle ScholarPubMed
37.Docherty, M, Bradford, HF, Joh, TH, et al. Specific lysis of noradrenergic synaptosomes by an antiserum to dopamine-ß-–hydroxylase. FEBS Lett 1986; 202: 37–40.CrossRefGoogle Scholar
38.Watts, H, Kennedy, PGE, Thomas, M, et al. The significance of antineuronal antibodies in Alzheimer’s disease. J Neuroimmunol 1981; 1: 107–116.CrossRefGoogle ScholarPubMed
39.Itagaki , S, McGeer, PL, Akiyama, H, et al. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer’s disease brain tissue. Neurosci Lett 1988; 91: 259–264.CrossRefGoogle ScholarPubMed
40.McGeer, PL, Itagaki, S, Tago, H, et al. Reactive microglia in patients with SDAT are positive for the histocomptability glycoprotein HLA-DR Neurosci Lett 1987; 79: 195–200.CrossRefGoogle Scholar
41.Pouplard-Barthelaix, A, Dubas, F, Maher, I,et al. Expression of HLA-DR (MHC class II molecules) in the brain: “in situ” demonstration of immunologic mechanisms in Alzheimer’s disease (AD, SDAT). Neurology 1987; 37: (Suppl) 225.Google Scholar
42.Wisniewski, HM, Kozlowski, PB. Evidence for blood-brain barrier changes in senile dementia of Alzheimer’s type (AD/SDAT): Alzheimer’s disease, Down’s syndrome and aging. Ann NY Acad Sci 1982; 386: 119–129.CrossRefGoogle Scholar
43.Adolfsson, R, Gottfries, CG, Roos, BE, et al. Changes in brain cate cholamines in patients with dementia of Alzheimer type. Br J Psychiatry 1979; 135: 216–223.CrossRefGoogle Scholar
44.Maragos, WF, Greenamyre, TJ, Penney, JB, et al. Glutamate dys function in Alzheimer’s disease: an hypothesis. TINS 1987; 10: 65–68.Google Scholar
45.Docherty, M, Bradford, HF, Wu, J-Y. Co-release of glutamate and aspartate from cholinergic and GABAergic synaptosomes. Nature 1987; 330: 64–66.CrossRefGoogle ScholarPubMed